Amyloid-Targeting Alzheimer’s Drugs Show No Meaningful Benefit and Increase Brain Risks
A Cochrane review of 17 trials (20,342 participants) finds anti-amyloid drugs for Alzheimer’s disease do not provide clinically meaningful cognitive or daily-function benefits in mild cognitive impairment or mild dementia and may raise risks of brain swelling and bleeding, despite removing amyloid-beta from the brain. The evidence suggests these drugs do not translate into patient benefit, prompting a shift toward exploring other treatment pathways.